<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Unknown</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6F3E082C-85BE-476C-BB2A-5353D9DB34A0"><gtr:id>6F3E082C-85BE-476C-BB2A-5353D9DB34A0</gtr:id><gtr:firstName>Tony</gtr:firstName><gtr:surname>Segal</gtr:surname><gtr:orcidId>0000-0001-7602-9043</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/094C190C-87A4-4F52-91A7-F7CF21F0644D"><gtr:id>094C190C-87A4-4F52-91A7-F7CF21F0644D</gtr:id><gtr:firstName>Derek</gtr:firstName><gtr:surname>Jewell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9EDF2627-245B-4CA0-963E-A1E33A3F2F3A"><gtr:id>9EDF2627-245B-4CA0-963E-A1E33A3F2F3A</gtr:id><gtr:firstName>Satish</gtr:firstName><gtr:surname>Keshav</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5DC49474-2A15-4DE5-B215-B90F79B360BC"><gtr:id>5DC49474-2A15-4DE5-B215-B90F79B360BC</gtr:id><gtr:firstName>Gordon</gtr:firstName><gtr:surname>MacPherson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7FF835E3-2A12-4297-9F07-DD8275601D72"><gtr:id>7FF835E3-2A12-4297-9F07-DD8275601D72</gtr:id><gtr:firstName>Siamon</gtr:firstName><gtr:surname>Gordon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/62ADFDCC-D255-40A8-A691-E25F1EF2813F"><gtr:id>62ADFDCC-D255-40A8-A691-E25F1EF2813F</gtr:id><gtr:firstName>Fiona</gtr:firstName><gtr:surname>Powrie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0200231"><gtr:id>C2C9188F-AE01-4526-A638-499AA557A714</gtr:id><gtr:title>Post-genomic approaches to inflammatory bowel disease - cell biology, pathophysiology, and therapeutics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0200231</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Inflammatory bowel disease (IBD) is a major health problem worldwide, for which exciting new genetic and pathophysiological research promises to yield advances that will increase our diagnostic and therapeutic capability. 
We propose to form a co-operative group that is uniquely placed both nationally and internationally to exploit these advances to further our understanding of IBD, and improve clinical practice. The co-operative includes Professor Jewell, who leads population-based IBD genetic research in the UK, Professor Segal, who contributes state-of-the art proteomics facilities, and leading experts in specialised cells that are involved in IBD pathogenesis: Dr Keshav (Paneth cells), Dr MacPherson (intestinal dendritic cells), Dr Powrie (regulatory T lymphocytes), Professor Gordon (macrophages), and Professor Segal (neutrophils). We are based in two Universities with outstanding biomedical research facilities, constituting an environment that will support our work. Our groups comprise basic science and clinical researchers who have worked together in the past, and continue to do so. 
By increasing interaction and collaboration between our groups, and holding regular scientific meetings, we will create a critical mass of investigators focussed on IBD, and a scientific community that will synergistically expand the scope and impact of our individual research, allowing us to initiate ambitious new projects. In particular, we will rapidly exploit the discovery of new genes by Professor Jewell?s group, by performing experimental studies using animal models and human tissue. Secondly, we will use our expert knowledge of specialised cells to identify new candidate genes, and to interrogate the existing DNA database more efficiently. Thirdly, we will collaborate to define critically important cell-cell interactions in intestinal inflammation, some of which we are already investigating. Finally, we will use proteomics to study the function of newly identified IBD susceptibility genes, and generically to study the secreted and regulated protein repertoire of specialised cells involved in IBD.</gtr:technicalSummary><gtr:fund><gtr:end>2008-05-20</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>69597</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Oxford IBD Cohort and Biobank</gtr:description><gtr:id>8B04881D-330E-4D77-9429-7AA7414BF132</gtr:id><gtr:impact>Nearly all patients with IBD in Oxford are now part of a formal research cohort. This effort includes Paediatric Gastroenterology, and Colorectal and Upper GI surgery.</gtr:impact><gtr:outcomeId>546443767634a4.69982340-1</gtr:outcomeId><gtr:partnerContribution>Provided the clinical infrastructure and access to Biomedical Research Centre funding for setting up the Cohort and Biobank.</gtr:partnerContribution><gtr:piContribution>Seting up the Oxford IBD Biobank required an understanding of current thinking on relevant pathogenic factors in IBD.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Cancer Institute</gtr:department><gtr:description>Role of NOD2 polymorphisms in haematological disease</gtr:description><gtr:id>1B496101-0247-4E80-98B6-349C5F735E11</gtr:id><gtr:impact>MD thesis awarded. Multi-disciplinary: Gastroenterology and Haematology</gtr:impact><gtr:outcomeId>3289252719D-1</gtr:outcomeId><gtr:partnerContribution>Provision of samples from donors and recipients in haematopoietic stem cell transplantation</gtr:partnerContribution><gtr:piContribution>Intellectual contribution, and technical expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BBC radio 4 programme</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ED86C403-EEDA-43FE-B64A-C64C27205603</gtr:id><gtr:impact>Interviewed on radio about the role of Paneth cells in IBD

Not known yet!</gtr:impact><gtr:outcomeId>81829BDCFB6</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Regional patient groups - National Association for Colitis and Crohn's disease</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0B95E86E-8078-418B-B281-E240C4837E5E</gtr:id><gtr:impact>Talking about research and its clinical impact to patients

Increased participation in research by patients, and offer of voluntary work in our group by a suitably qualified patient</gtr:impact><gtr:outcomeId>7376BD9B8AC</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>85000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NACC Research Grant</gtr:description><gtr:end>2007-01-02</gtr:end><gtr:fundingOrg>National Association for Colitis and Crohn?s Disease (NACC)</gtr:fundingOrg><gtr:id>4B0F3ADD-122A-47A7-9C03-F9CF102A4335</gtr:id><gtr:outcomeId>D341A8E55EF0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2005-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CICRA Clinical Research Training Fellowship</gtr:description><gtr:end>2006-06-02</gtr:end><gtr:fundingOrg>Crohn's in Childhood Research Association (CICRA)</gtr:fundingOrg><gtr:id>C71B8A69-BE11-4B24-A476-9E21F68E1070</gtr:id><gtr:outcomeId>DA9E4E9EAE30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2004-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NACC Research Grant</gtr:description><gtr:end>2006-04-02</gtr:end><gtr:fundingOrg>National Association for Colitis and Crohn?s Disease (NACC)</gtr:fundingOrg><gtr:id>96BE4A98-3E6C-4D0A-BFBD-DB288B1B9BD5</gtr:id><gtr:outcomeId>6B9281DB8660</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2003-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Paneth cells are now regarded as a major cell involved in the pathogenesis of Crohn's disease</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>94B9C4FE-449D-4A75-9E5A-8E2FF5A92ABE</gtr:id><gtr:outcomeId>1A0C2F3B35F</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Sacral nerve stimulation using a commercially produced and marketed device can be used potentially to exploit the cholinergic anti-inflammatory response in IBD. We have, with funding from the Oxford BRC, completed a pilot clinical study that shows promise. The next step is to seek further funding to continue this study in a larger cohort of patients.</gtr:description><gtr:id>C77EBAB6-F5BB-4C9A-81A0-5DFC6ACCC596</gtr:id><gtr:impact>This was the first use of this device to treat IBD, and so far the only such use. The effects seen in this pilot study has led to interest from other centres and potential opportunities for collaboration and further investigation.</gtr:impact><gtr:outcomeId>54644ae70fc3a7.55652531</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Sacral Nerve Stimulation in IBD</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>All IBD patients at Oxford University Hospitals NHS Trust included in a prospective research cohort with associated biobank and database</gtr:description><gtr:id>3D8DA110-F902-46FB-BF4F-966EBC8ED82E</gtr:id><gtr:impact>All patients in the cohort of over 2,000 patients have provided informed consent to have data and tissue collected and used in ethically approved research. This has supported a wide range of basic and translational research projects in Oxford. The cohort and database have also supported numerous collaborative research projects with academic and commercial partners.</gtr:impact><gtr:outcomeId>5463dc9e16b510.86742733</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Oxford IBD Cohort Database and Biobank</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>407A9DC5-DBA7-486D-821A-5F970069B60D</gtr:id><gtr:title>Predicting the Individual Risk of Acute Severe Colitis at Diagnosis.</gtr:title><gtr:parentPublicationTitle>Journal of Crohn's &amp; colitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3336e16341c5bee02f5cdf4ef67698f9"><gtr:id>3336e16341c5bee02f5cdf4ef67698f9</gtr:id><gtr:otherNames>Cesarini M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1873-9946</gtr:issn><gtr:outcomeId>5aa8db29362319.06212081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E42E510-B854-40FC-861E-2EF4D163A4F7</gtr:id><gtr:title>Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/272ab49bebdb3e7648af5c47b35d405e"><gtr:id>272ab49bebdb3e7648af5c47b35d405e</gtr:id><gtr:otherNames>Mayor NP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>67D7119AC9F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD3D0DD4-6991-408A-82F3-83E4E12A5EA2</gtr:id><gtr:title>Does Disease Extent Matter when Scoring the UCEIS?</gtr:title><gtr:parentPublicationTitle>Journal of Crohn's &amp; colitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4e64c34aaae304b77559843fb6dcff8"><gtr:id>a4e64c34aaae304b77559843fb6dcff8</gtr:id><gtr:otherNames>Travis S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1873-9946</gtr:issn><gtr:outcomeId>56e07308917c02.52118765</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D462A7C7-EBA2-42AF-8283-0FEDCDEED832</gtr:id><gtr:title>CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8707ea8442682f77bc40903e3f00603b"><gtr:id>8707ea8442682f77bc40903e3f00603b</gtr:id><gtr:otherNames>Wendt E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1178-7023</gtr:issn><gtr:outcomeId>56e0736e58efd5.43849944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D009FF34-A018-4CEC-A4B8-A5FB718EF696</gtr:id><gtr:title>Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/163990a608361790caa5b314f852d76f"><gtr:id>163990a608361790caa5b314f852d76f</gtr:id><gtr:otherNames>Bryant RV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>56e0736e2fa7a2.85095002</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF4AEB23-F350-48B0-9087-26374FFEACA3</gtr:id><gtr:title>Circulating and Tissue-Resident CD4T Cells With Reactivity to Intestinal Microbiota Are Abundant in Healthy Individuals and Function Is Altered During Inflammation.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66a85b821d98d5e3389a53cf5bf5db99"><gtr:id>66a85b821d98d5e3389a53cf5bf5db99</gtr:id><gtr:otherNames>Hegazy AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>5aa8d9ab8340f8.01939909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45E76024-C29A-4C14-8713-7BAB1DE16F9A</gtr:id><gtr:title>Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacology and experimental therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b19ccd4d33d40c0226af88375443265"><gtr:id>0b19ccd4d33d40c0226af88375443265</gtr:id><gtr:otherNames>Walters MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3565</gtr:issn><gtr:outcomeId>EBDnzxVTHvw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>888D1FFD-626A-4CB7-B348-0AC91674EE32</gtr:id><gtr:title>Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis.</gtr:title><gtr:parentPublicationTitle>Journal of Crohn's &amp; colitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2fc6fbf3981de75af5c9e7804c49654"><gtr:id>d2fc6fbf3981de75af5c9e7804c49654</gtr:id><gtr:otherNames>Guirgis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1873-9946</gtr:issn><gtr:outcomeId>5aa8db28ea4152.02030253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE53FB19-99C3-4344-AE96-76768F472190</gtr:id><gtr:title>The pathogen recognition sensor, NOD2, is variably expressed in patients with pulmonary tuberculosis.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3960846f2d16de98dddc33560a5c3ea5"><gtr:id>3960846f2d16de98dddc33560a5c3ea5</gtr:id><gtr:otherNames>Lala S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>8A209DE7A5C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A75130E-5504-4BD0-8B76-FE0FC283786A</gtr:id><gtr:title>Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d2c85175a039336754b1b2920fbba72"><gtr:id>5d2c85175a039336754b1b2920fbba72</gtr:id><gtr:otherNames>Danese S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>5464405321ae71.46103097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CC4135C-40A3-41B3-ABB9-0FF23940BF33</gtr:id><gtr:title>A rare cause of bloody diarrhoea.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a50b7f86a652517d0cb7d1da4d96b549"><gtr:id>a50b7f86a652517d0cb7d1da4d96b549</gtr:id><gtr:otherNames>Culver EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>pm_16440_20_21508420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9098FB18-158D-4195-BEC6-AE9D10917DF2</gtr:id><gtr:title>A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2092b334d5dafab53978f4c41a58a3d9"><gtr:id>2092b334d5dafab53978f4c41a58a3d9</gtr:id><gtr:otherNames>Keshav S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16440_20_23527300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D867183A-051E-47CB-9EA9-EC6BAB120CAE</gtr:id><gtr:title>Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis.</gtr:title><gtr:parentPublicationTitle>Journal of Crohn's &amp; colitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af213ddff03f5529aeb9a3b0358fff0f"><gtr:id>af213ddff03f5529aeb9a3b0358fff0f</gtr:id><gtr:otherNames>Corte C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1873-9946</gtr:issn><gtr:outcomeId>56e073e3cdf382.38105813</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6166B265-F9B7-4783-B1E7-35277CAB76E3</gtr:id><gtr:title>A novel technique for NOD2/CARD15 genotyping using PCR-SSP.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/272ab49bebdb3e7648af5c47b35d405e"><gtr:id>272ab49bebdb3e7648af5c47b35d405e</gtr:id><gtr:otherNames>Mayor NP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>08C32568805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B75B84C1-DCF6-4502-AD12-6961545E5263</gtr:id><gtr:title>The role of a defunctioning stoma for colonic and perianal Crohn's disease in the biological era.</gtr:title><gtr:parentPublicationTitle>Scandinavian journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a820cde586c08d8b4c38c3d3eaf8f506"><gtr:id>a820cde586c08d8b4c38c3d3eaf8f506</gtr:id><gtr:otherNames>Mart?-Gallostra M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0036-5521</gtr:issn><gtr:outcomeId>5aa8db291953f8.76426608</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F33B18E-A1D8-4B3C-8B4B-EA94328519DB</gtr:id><gtr:title>Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy.</gtr:title><gtr:parentPublicationTitle>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f58740fa77bb715ab961554cb805780f"><gtr:id>f58740fa77bb715ab961554cb805780f</gtr:id><gtr:otherNames>Hoffmann B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1542-3565</gtr:issn><gtr:outcomeId>41220896A6D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>832E4DE7-BC11-42BE-88F6-9A6260F8CA30</gtr:id><gtr:title>Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4596ee70ba87c18360617a95487bcd71"><gtr:id>4596ee70ba87c18360617a95487bcd71</gtr:id><gtr:otherNames>West NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>5aa8db289e5ca3.71408109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75454467-376F-4E04-B6F7-2751A3234FD2</gtr:id><gtr:title>Comparing disease activity indices in ulcerative colitis.</gtr:title><gtr:parentPublicationTitle>Journal of Crohn's &amp; colitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e51cf8fcf91d1ea95b733b6ba0280287"><gtr:id>e51cf8fcf91d1ea95b733b6ba0280287</gtr:id><gtr:otherNames>Walsh AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1873-9946</gtr:issn><gtr:outcomeId>pm_16440_20_24120021</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA16D842-306D-4620-8F05-ADF3868ACBDB</gtr:id><gtr:title>Ratiometric analysis of fura red by flow cytometry: a technique for monitoring intracellular calcium flux in primary cell subsets.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5f9d1ebce16ab97bba7f2866debf3ab"><gtr:id>f5f9d1ebce16ab97bba7f2866debf3ab</gtr:id><gtr:otherNames>Wendt ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56e0736e7b9ca4.22563225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86E1933A-44F7-40CB-97BC-2341D621089B</gtr:id><gtr:title>Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae95f0cbe24dd2d4fe4bb815c3e79172"><gtr:id>ae95f0cbe24dd2d4fe4bb815c3e79172</gtr:id><gtr:otherNames>Reenaers C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>pm_16440_20_23061650</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F784E3D3-159B-48CB-8DEC-84873D8727EE</gtr:id><gtr:title>A basal gradient of Wnt and stem-cell number influences regional tumour distribution in human and mouse intestinal tracts.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c855b5df4a1ef6225272a4bcd6066882"><gtr:id>c855b5df4a1ef6225272a4bcd6066882</gtr:id><gtr:otherNames>Leedham SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>pm_16440_20_22287596</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AB93C0C-B759-4FBA-8435-9DA91C692B3A</gtr:id><gtr:title>Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4596ee70ba87c18360617a95487bcd71"><gtr:id>4596ee70ba87c18360617a95487bcd71</gtr:id><gtr:otherNames>West NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>5aa8db28c4f732.68714677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC2DBD03-9FC6-43DF-8D08-E8D9EFBCDC17</gtr:id><gtr:title>Molecular epidemiology of Clostridium difficile strains in children compared with that of strains circulating in adults with Clostridium difficile-associated infection.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d73baf845cafdc73ad61e92bec2ca251"><gtr:id>d73baf845cafdc73ad61e92bec2ca251</gtr:id><gtr:otherNames>Stoesser N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>MnUgyCpA9i9</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0200231</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>